IBD patients may ditch IV drips for simple shots

NCT ID NCT06381518

Completed Disease control Sponsor: Zuyderland Medisch Centrum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested switching 38 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) from intravenous infliximab to a subcutaneous (under-the-skin) injection. Researchers measured drug levels, quality of life, and patient satisfaction over 24 weeks. The goal was to see if the switch maintains effectiveness while being more convenient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab (CT-P13, a biosimilar) given as a subcutaneous injection
What this could lead to: If successful, this could show that switching to a subcutaneous injection is just as effective and more convenient for patients with inflammatory bowel disease.
What could go wrong: This is a small, single-center study with only 38 patients, so results may not apply to everyone. The switch might not work as well for some patients, and there is a risk of injection site reactions or loss of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE IBD INFLIXIMAB ULCERATIVE COLITIS

Contacts and locations

Locations

Zuyderland Medical Centre

Sittard, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.